Skip to main content

Advertisement

SpringerLink
Log in

Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    CAS  PubMed  Google Scholar 

  2. De Wit D, van Erp NP, Khosravan R, Wiltshire R, Allred R, Demetri GD, Guchelaar HJ, Gelderblom H (2014) The influence of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer 14:575–583

    Article  PubMed Central  PubMed  Google Scholar 

  3. van Erp NP, de Wit D, Guchelaar HJ, Gelderblom H, Hessing TJ, Hartigh J (2013) A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 937:33–43

    Google Scholar 

  4. Drug monograph Pr VOTRIENT® (Pazopanib) GlaxoSmithKline, January 2014

  5. Medication Guide, Food and Drug Administration. (www.fda.gov)

  6. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors. Focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50(9):551–603

    Article  PubMed  Google Scholar 

  7. Van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692–706

    Article  PubMed  Google Scholar 

  8. Adams VR, Leggas M (2007) Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 29:1338–1353

    Article  CAS  PubMed  Google Scholar 

  9. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamics meta-analysis. Cancer Chemother Pharmacol 66:357–371

    Article  CAS  PubMed  Google Scholar 

  10. De Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, König-Quartel JMC, Hessing T, Guchelaar HJ, van Erp NP (2013) Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer. Cancer Chemother Pharmacol 73(1):87–96

    Article  PubMed  Google Scholar 

  11. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2005) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–3

    Article  PubMed  Google Scholar 

  12. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JÖ, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 9:327–337

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Internal Medicine, Reinier de Graaf Group of Hospitals, Reinier de Graafweg 3-11, 2625 AD, Delft, The Netherlands

    Caroline M J van Kinschot & Vincent O. Dezentjé

  2. The Department of Pharmacology, Reinier de Graaf Group of Hospitals, Reinier de Graafweg 3-11, 2625 AD, Delft, The Netherlands

    Nielka P. van Erp

  3. The Department of Pharmacology, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 GA, Nijmegen, The Netherlands

    Tanja Feberwee

Authors
  1. Caroline M J van Kinschot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nielka P. van Erp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanja Feberwee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincent O. Dezentjé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline M J van Kinschot.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van Kinschot, C.M.J., van Erp, N.P., Feberwee, T. et al. Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery. Eur J Clin Pharmacol 71, 1279–1281 (2015). https://doi.org/10.1007/s00228-015-1902-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1902-3

Keywords

Search

Navigation